Please assess the completion status of the following clinical trial:

Trial Title: The MONOVISC Hip Osteoarthritis Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female ≥ 30 years old~* Body Mass Index (BMI) ≤ 35~* Clinical or radiographic diagnosis of hip osteoarthritis in the target hip, with a Kellgren-Lawrence (K/L) grade of 2 or 3.~* Walking pain NRS ≥ 4 and ≤ 8.~* Willing to discontinue all pain medications (except rescue medication) for 7 days prior to the first study injection and for the duration of the study.~* Willing to discontinue rescue medication for 48 hours prior to the first study injection.~* Willing to discontinue rescue medication for 48 hours prior to all follow-up visits~* Ability to tolerate acetaminophen (e.g. Tylenol).~* Must be physically and mentally willing and able to comply with pre and post-treatment scheduled clinical and radiographic evaluations~* Must voluntarily sign the Institutional Review Board approved Informed Consent Form.~* Must agree not to initiate cannabis therapy during the trial study period.~Exclusion Criteria:~* Radiographic evidence of osteonecrosis in the target hip~* NRS walking pain ≥ 3 the contralateral hip~* Clinically diagnosed osteoarthritis in either knee resulting in walking pain greater than NRS 5.~* Dependence on external stabilization for walking (e.g. cane, crutches, walker, etc.)~* Pain associated with lower back disorders that cannot be differentiated from target hip pain~* Major dysplasia or congenital abnormality~* Diagnosis of fibromyalgia~* Primary inflammatory arthropathy, or any other condition affecting the joint, including rheumatoid arthritis or gout in the target hip~* Any musculoskeletal condition that could impede efficacy measurement of the target hip~* Any major surgery, arthroplasty, or arthroscopy of the lower extremities in the past 6 months, or planned surgery during the study~* Infection of the injection site area~* Chronic skin disorders that could interfere with injection site evaluation~* Patients with asthma who require systemic use of corticosteroids~* Septic arthritis in any joint in the past 12 weeks~* For all patients: known hypersensitivity to hyaluronan, lidocaine, or acetaminophen~* For patients undergoing fluoroscopic injection guidance: known hypersensitivity to iodine-based fluoroscopic contrast agents, shellfish, or iodine~* Intra-articular steroid injection of the target hip within the last 3 months or hyaluronan injection of the target hip within the last 26 weeks~* Systemic corticosteroids within the last 12 weeks~* Glucosamine and/or chondroitin sulfate within last 4 weeks~* Currently on anticoagulation therapy, including aspirin therapy of \> 81 mg/day (e.g. one daily baby aspirin).~* Uncontrolled diabetes mellitus.~* Pregnant or breast feeding, or plan to be pregnant during the course of the study~* Any significant illness (metastasis of any type) that decreases the probability of the subject's survival to the 26 week endpoint~* Patients unwilling/unable to complete a pain/function and quality of life questionnaires~* Significant trauma to the index hip within 26 weeks of screening~* Is receiving workman's compensation, or is currently involved in litigation relating to hip osteoarthritis~* Is receiving prescription pain medication for conditions unrelated to hip osteoarthritis~* Chronic use of narcotics~* Unwilling to return for follow-up visits as described in this protocol~* Otherwise determined by the investigator to be medically unsuitable for participation in this study

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MONOVISC (Type: EXPERIMENTAL): MONOVISC High Molecular Weight Hyaluronan
- Saline (Type: PLACEBO_COMPARATOR): Physiologic saline

Based on this trial design, predict the completion outcome and termination type (if applicable).